Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Next Previous
Trial Profile

Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use

Most Recent Events

  • 15 Nov 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top